首页 > 市场调查报告书 > 製药

麻醉

市场调查报告书

商品编码

1622414

全身麻醉剂市场规模、份额、成长分析，按药物类型、给药途径、最终用途和地区划分 - 产业预测，2025-2032 年

General Anesthesia Drugs Market Size, Share, Growth Analysis, By Drug Type (Propofol, Sevoflurane), By Route of Administration (Intravenous, Inhaled), By End-Use, By Application, By Region - Industry Forecast 2025-2032

出版日期: 2024年12月22日 | 出版商:

SkyQuest | 英文 260 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2023年全身麻醉剂市场规模为55.9亿美元，从2024年的57.9亿美元成长到2032年的79.7亿美元，预计复合年增长率为3.5%。

全身麻醉市场正在经历显着增长，这主要是由于手术数量的增加和新麻醉剂的引入。全球每年进行 3.1 亿例大型手术，美容和重组手术显着增加，心血管疾病和慢性肾臟病者对静脉 (IV)麻醉剂的需求尤其强劲。 PainPass 的 CBD/Lidocaine係列和 Hikma Pharmaceuticals 的Bupivacaine注射液等创新局部麻醉剂进一步促进了市场扩张。此外，PAION AG 的 Byfavo 等程序性镇静剂的监管环境也在不断变化。这些趋势显示全身麻醉市场强劲，手术量和产品创新不断增加。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东/非洲
- 海湾合作委员会国家
- 南非
- 其他中东/非洲

竞争资讯

前5名企业对比
主要企业市场定位（2024年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2024年）
主要企业简介
- 公司简介
- 产品系列分析
- 按细分市场分類的份额分析
- 收益与前一年同期比较（2022-2024）

主要企业简介

AstraZeneca（UK）
Baxter International Inc.（USA）
Fresenius SE & Co. KGaA（Germany）
AbbVie Inc.（USA）
B. Braun Melsungen AG（Germany）
Hikma Pharmaceuticals PLC（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Pfizer Inc.（USA）
Novartis AG（Switzerland）
Mylan NV（USA）
Piramal Enterprises Limited（India）
Eisai Co., Ltd.（Japan）
F. Hoffmann-La Roche Ltd.（Switzerland）
GlaxoSmithKline plc（UK）
Johnson & Johnson（USA）
Merck & Co., Inc.（USA）
Sanofi SA（France）
Sun Pharmaceutical Industries Ltd.（India）
Takeda Pharmaceutical Company Limited（Japan）
Abbott Laboratories（USA）

结论和建议

简介目录

Product Code: SQSG30B2035

General Anesthesia Drugs Market size was valued at USD 5.59 Billion in 2023 and is poised to grow from USD 5.79 Billion in 2024 to USD 7.97 Billion by 2032, growing at a CAGR of 3.5% during the forecast period (2025-2032).

The general anaesthesia market is witnessing significant growth, primarily driven by the rising number of surgical procedures and the introduction of new anaesthetic medications. With 310 million major surgeries conducted globally each year and a notable increase in cosmetic and reconstructive procedures, the demand for intravenous (IV) anaesthetics is escalating, particularly for patients with cardiovascular and chronic renal diseases. Innovative local anaesthetic products, such as PainPass's CBD/lidocaine line and Hikma Pharmaceuticals' Bupivacaine HCl Injection, further contribute to market expansion. Additionally, regulatory approvals like PAION AG's Byfavo for procedural sedation demonstrate an evolving landscape. These trends indicate a robust market trajectory for general anaesthesia as both surgical volumes and product innovations continue to rise.

Top-down and bottom-up approaches were used to estimate and validate the size of the General Anesthesia Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

General Anesthesia Drugs Market Segmental Analysis

Global General Anesthesia Drugs Market is segmented by drug type, Route of Administration, end-use, application and region. Based on drug type, the market is segmented into propofol, sevoflurane, desflurane, ketamine, thiopental, etomidate and others. Based on route of administration, the market is segmented into intravenous and inhaled. Based on end-use, the market is segmented into hospitals, ambulatory surgical centers, clinics and others. Based on application, the market is segmented into cardiovascular surgery, orthopedic surgery, neurosurgery, general surgery, cosmetic surgery and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the General Anesthesia Drugs Market

The growth of the general anesthesia drugs market is significantly driven by the rising incidence of cancer in the United States. Recent estimates from the National Cancer Institute indicate that there are currently around 16.9 million cancer survivors, with projections suggesting this figure could reach 22.2 million by 2030. The prevalence of various cancers, including lung, breast, and prostate cancer, is increasing, which leads to a greater need for surgical interventions. As surgeries, particularly for malignant tumors, present the most effective treatment option when cancer is localized, the demand for general anesthesia is expected to rise correspondingly, propelling the market forward.

Restraints in the General Anesthesia Drugs Market

The General Anesthesia Drugs market faces significant restraint due to the associated risks in pediatric patients and pregnant women. Caution is paramount when administering general anesthetics to infants and young children, as their physiological responses differ from adults, influenced by aspects like body composition and the maturation of organ functions. Research has highlighted potential dangers, such as extensive nerve cell death in young animals following prolonged exposure to these drugs, leading to increased scrutiny within human studies. The FDA has further issued warnings about the risks of prolonged or repeated use in children under three and pregnant women, leading healthcare providers to reconsider the adoption of these anesthetic treatments, which may hinder market growth.

Market Trends of the General Anesthesia Drugs Market

The General Anesthesia Drugs market is witnessing significant growth, driven by intensive research and development efforts aimed at enhancing clinical outcomes and patient recovery. Notable studies, such as those from the University of Michigan and Washington University School of Medicine, are assessing the efficacy of existing anesthetics, including inhaled agents and intravenous propofol, to refine usage protocols. This focus on evidence-based practice is poised to improve patient care, making anesthetics safer and more effective. As a result, the market is likely to expand, fueled by innovations that meet the increasing demands of surgical procedures and patient safety standards throughout the forecast period.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis

Global General Anesthesia Drugs Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Propofol
Sevoflurane
Desflurane
Ketamine
Thiopental
Etomidate
Others

Global General Anesthesia Drugs Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Intravenous
- Bolus Injection
- Continuous Infusion
Inhaled
- Volatile Liquids
- Gases

Global General Anesthesia Drugs Market Size by End-Use & CAGR (2025-2032)

Market Overview
Hospitals
Ambulatory Surgical Centers
Clinics
Others

Global General Anesthesia Drugs Market Size by Application & CAGR (2025-2032)

Market Overview
Cardiovascular Surgery
Orthopedic Surgery
Neurosurgery
General Surgery
Cosmetic Surgery
Others

Global General Anesthesia Drugs Market Size & CAGR (2025-2032)

North America (Drug Type, Route of Administration, End-Use, Application)
- US
- Canada
Europe (Drug Type, Route of Administration, End-Use, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Route of Administration, End-Use, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Route of Administration, End-Use, Application)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Route of Administration, End-Use, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun Melsungen AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Enterprises Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments